Volume 9, Number 1—January 2003
Research
Cost Effectiveness of a Potential Vaccine for Human papillomavirus
Gillian D. Sanders*
and Al V. Taira*
and Al V. Taira*
Table 1
Health and economic outcomes of HPV vaccinationa
| Outcome | No vaccination | HPV vaccination |
|---|---|---|
| Cost, $ | 39,682 | 39,928 |
| Incremental cost, $ | 246 | |
| Life expectancy, yrs | 28.785 | 28.793 |
| Incremental life expectancy, days | 2.8 | |
| Quality-adjusted life expectancy, yrs | 27.720 | 27.731 |
| Incremental quality-adjusted life expectancy, days | 4.0 | |
| Incremental cost effectiveness | ||
| $/life year | 32,066 | |
| $/quality-adjusted life year | 22,755 |
aHPV, Human papillomavirus.
Page created: December 07, 2010
Page updated: December 07, 2010
Page reviewed: December 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.